BXQ-350 Neuroprotective Outcomes in Chemotherapy Induced Peripheral Neuropathy (CIPN) Patients

During Bexion’s Phase 1 study of BXQ-350 in adult patients with advanced solid tumors, a patient self-reported complete resolution of long term, persistent Chemotherapy Induced Peripheral Neuropathy (CIPN).  Due to this unexpected reporting, Bexion elected to explore this finding further by reviewing data from a cohort of patients who had entered the study with peripheral neuropathy, largely due to prior chemotherapy treatments.

Peripheral Neuropathy:
Anecdotal Results from Phase 1 Cohort1

CIPN chart

Highlights of Study 1

  • 73%: Reported Symptom Improvement
  • Subjects who did not report symptom improvement had relatively mild CIPN.
  • Short term persistence may have been coincidental to termination of offending chemotherapy.
  • Resolution of long term persistent peripheral neuropathy is “unexpected and surprising”.
  • 5 of 6 long-term, persistent peripheral neuropathy subjects improved while on BXQ-350

“Chemotherapy-induced peripheral neuropathy (CIPN) remains an unmet clinical need affecting far too many patients. We are excited to bring into the clinic an exciting new approach incorporating our unique knowledge at the molecular level to treating this important condition, and to potentially treat other forms of neuropathy”

Ray Takigiku, Ph.D. , President and CEO, Bexion Pharmaceuticals
References
  1. Anecdotal patient reports from clinical study of BXQ-350.AA, in progress. The safety and efficacy of BXQ-350 are current being evaluated in clinical trials.
Neuroprotective Outcomes
Market Opportunity
What is CIPN?
Impact of CIPN